Grace Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Grace Therapeutics, Inc. (GRCE) filed a Current Report on Form 8-K dated January 10, 2026. The filing addresses Item 5.02 regarding amendments to the employment agreements of five executive officers. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
Material Changes
On January 10, 2026, the Company entered into amendments to the letter agreements of the following executives:
- Prashant Kohli (Chief Executive Officer)
- Robert J. DelAversano (Principal Financial Officer and Vice President, Finance)
- Amresh Kumar (Vice President, Program Management)
- Carrie D’Andrea (Vice President, Clinical Operations)
- R. Loch Macdonald (Chief Medical Officer)
The amendments supersede and replace certain severance terms in the original agreements. Key changes include:
- Termination without Cause (No Change in Control): Executives are entitled to accrued obligations plus 6 months of base salary and COBRA premiums (12 months for the CEO). Unvested equity awards are forfeited.
- Termination without Cause or Resignation for Good Reason (Within 12 months of Change in Control): Executives are entitled to accrued obligations plus a cash payment equal to 6 months of base salary plus target bonus (18 months for the CEO) and COBRA premiums for the same duration. Unvested equity awards become fully vested and exercisable.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary risk disclosed relates to the increased potential liability for severance payments and equity acceleration in the event of a Change in Control or specific terminations.
Investor Verification Checklist
- Review the full text of the attached exhibits (10.1 through 10.5) to understand specific definitions of "Cause," "Good Reason," and "Change in Control."
- Verify the total potential cash and equity liability exposure for the Company under the new severance terms.
- Confirm the current status of unvested equity awards held by the named executives to assess the impact of the acceleration clause.
- Check for any related proxy statements or 10-Q filings that may provide context on the company's cash position relative to these new obligations.